Related Experiment Video
Updated: Jul 14, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Effect of PON1 polymorphism on HDL antioxidant potential is blunted with aging
Mounia Cherki1, Hicham Berrougui, Maxim Isabelle
1Research Centre on Aging, Sherbrooke Geriatric University Institute, 1036 Belvedere South, Sherbrooke, Quebec, Canada.
Abstract:
Paraoxonase1 is a HDL-associated enzyme, which is responsible for their antioxidant property. This study was aimed to investigate the effect of PON1 [Q192R] and [L55M] genotypes on susceptibility of LDL and HDL to lipid peroxidation and on antioxidant activity of HDL as a function of aging. Seventy-eight healthy subjects distributed in two age groups, young (20-30 years) and elderly (60-89 years) were recruited. PON1 activities and genotype polymorphisms were determined for each subject. LDL and HDL susceptibility to lipid peroxidation was evaluated by the measure of lag-phase (LP) for conjugated diene formation. HDL antioxidant property was evaluated by the measure of their capacity to protect LDL against lipid peroxidation. Our results show that LP for LDL and HDL peroxidation decreased with age of donors. Moreover, PON1 genotypes affect significantly the susceptibility of LDL and HDL to lipid peroxidation. Furthermore, basal- and salt-stimulated paraoxonase as well arylesterase activities were significantly reduced in elderly compared to young subjects. These results show a beneficial effect of PON1 towards susceptibility of HDL to oxidation as well to their antioxidant effect. However, this PON1 protective effect seems to be blunted with advancing age. Altogether our results suggest that the decrease in the PON1 protective effect with aging may contribute to the acceleration of the atherosclerosis process in elderly.
Related Concept Videos
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Peroxisomes
Pharmacodynamics in Geriatric Patients: Effects of Age
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
